EGFR Inhibitors, Compositions and Methods Thereof

A compound of Formula I, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug, chelate, non-covalent complex, or solvate thereof,

• wherein,
• R1 is H, CN, halogen, —C1-6 alkyl or C1-6 alkoxyl;
• R2 is H, halogen, or —C1-6 alkyl;
• or
• R1 and R2 together with the atoms to which they are attached form a 5- to 6-membered heteroaryl ring optionally comprising 1, 2 or 3 hetero atoms independently selected from N, S, or O;
• R3 is H, halogen, —C1-6 alkyl, —C1-4 haloalkyl, —C3-6 carbocyclic ring;
• R4 and R5 are each independently selected from H, —C1-6 alkyl, —C1-4 alkyl-OH, or —C3-6 carbocyclic ring;
• or
• R4 and R5 together with the atoms to which they are attached form a 5- to 6-membered heterocyclic ring optionally substituted with one or more substituents independently selected from —C1-6 alkyl, halogen, or —NR6R7;
• R6 and R7 are each independently selected from H, or —C1-6 alkyl;
• m, n, m′, and n′ are each independently selected from 1 or 2.